ADFORM
29.9.2020 12:20:14 CEST | Business Wire | Press release
Adform , the only independent global ad management platform covering all aspects of the digital campaign lifecycle, today introduced its new product suite: Adform FLOW. Intuitively designed to make it easier for marketers to plan, buy and activate media, Adform FLOW has everything they need in one easy-to-use platform: DSP, DMP, SSP, DCO and ad server. Through exceptional user experience and enhanced human/machine collaboration, Adform FLOW provides augmented intelligence to amplify business results.
Features of Adform FLOW include:
- Seamless and integrated User Experience, across all aspects of the campaign workflow and all digital media channels
- SaaS technology, which provides increased control and flexibility; including a modular and open API approach, coupled with the ability to control costs through license-based fees
- First-party identity-ready, setup for privacy compliance and a post-cookie world
- Media-neutrality, with no media or data ownership, and therefore no conflicts
Adform research, conducted in partnership with Dynata and surveying more than 1,000 marketers, shows almost three-quarters of modern marketers (74%) want a single dashboard to manage campaigns efficiently, with top benefits cited as data optimisation, cost efficiencies and control.
Now, more than three years in the making and building on Adform’s two decades of innovation, Adform FLOW is enterprise technology built for modern marketing: independent and integrated, giving marketers enhanced control over their own data, that they have not been able to realise through previous solutions. It is configurable, transparent and secure, enabling seamless management of campaigns.
Digital marketers have long struggled with the inefficiencies presented by the myriad of martech and adtech solutions they deploy, and today’s economic realities make the push for efficiency that much more urgent. Some companies have operated within walled gardens; others have sought out best-of-breed technologies and patched together point solutions that fail to work well together. Adform FLOW provides the feature richness of a complex point solution setup, with the scale, ease of use and efficiency of walled gardens.
Samir Shah, Managing Partner – Data, Technology & Programmatic at Zenith said: "I have been impressed at how Adform has continued to develop its platform, the efficiency gains reported are significant. Via their solutions I can see strategic benefits, particularly during a time of complexity in the market being aligned to the future of first-party IDs, and being able to differentiate is key.”
“Modern marketers need a complete solution that is customisable to their particular needs. We are certain that we can add significant value to our clients by enabling them to do more than they've been able to do before,” said Troels Jensen, CEO of Adform. “As the only independent fully integrated marketing platform, Adform offers transparency, privacy, and ownership of data. By addressing these challenges, Adform's clients benefit from Adform FLOW's unique architecture and are able to secure significantly stronger results.”
About Adform
Adform is the only global, independent and fully integrated advertising platform built for modern marketing. Its unique enterprise technology – Adform FLOW – harnesses superior user experience and a scalable, modular and open architecture, to enable seamless management of the whole campaign lifecycle. It provides clients with enhanced control and transparency across their advertising operations, including ownership of all data from their campaigns. Since 2002, Adform has developed technology to enhance human/machine collaboration and deliver augmented intelligence, thereby amplifying business results for its clients around the world.
For more information, please visit: www.adform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom